Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Health Psychol ; 13(7): 912-20, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18809642

RESUMO

This study aimed to investigate the effects of preferred music listening on anxiety and pain perception in patients undergoing haemodialysis. A two group experimental design was used. Sixty people diagnosed with end stage renal failure undergoing haemodialysis treatment participated in this study. Preferred music listening was applied as an intervention. Anxiety and pain were measured pre-test and post-test. The control group scored significantly higher in state anxiety than the experimental group and experienced significantly higher pain intensity in post-test phase. Findings provide experimental evidence to support the effectiveness of preferred music listening in medical settings.


Assuntos
Ansiedade/psicologia , Falência Renal Crônica/psicologia , Musicoterapia , Dor/psicologia , Diálise Renal/psicologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Analgésicos/administração & dosagem , Ansiedade/diagnóstico , Medo , Feminino , Humanos , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Dor/diagnóstico , Medição da Dor/psicologia , Inventário de Personalidade/estatística & dados numéricos , Psicometria , Fatores Sexuais , Papel do Doente , Adulto Jovem
2.
Transplant Proc ; 35(4): 1364-7, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12826160

RESUMO

To assess the time-dependent changes in renal function in relation to antioxidant and lipid-lowering effects of fluvastatin in hyperlipidemic renal transplant recipients, 20 patients were treated with fluvastatin 40 mg/d for 12 months, after failure of a dietary program. Plasma malondialdehyde (MDA) levels and lipid profiles were evaluated in relation to serum creatinine and calculated creatinine clearances 18 months before and during the fluvastatin treatment. Mean baseline lipid values were: total cholesterol 318 mg/dL, triglycerides 212 mg/dL, LDL cholesterol 219 mg/dL, HDL cholesterol 58 mg/dL, apolipoprotein A 176 mg/dL, and apolipoprotein B 145 mg/dL. During 12 months of treatment, fluvastatin produced consistent and significant reductions in total and LDL cholesterol (-18.4% and -24.1%), triglycerides (-17.7%), and apolipoprotein B (-22.7%) as well as an increase in HDL cholesterol (12.3%) and apolipoprotein A (9.2%). Plasma MDA levels decreased by 41.8% (from 3.5 +/- 0.3 to 1.8 +/- 0.1 nmol/mL, P =.00002). Creatinine clearance, which had been declining at a rate of 0.32 mL/min/month during the previous 18 months before treatment, progressively improved during treatment, giving a positive slope of the creatinine clearance, which increased by 0.35 mL/min/month, (P =.016; 53.3 +/- 4.2 mL/min vs 49.8 +/- 4.1 mL/min pretreatment). Multiple linear regression analysis revealed that MDA was the parameter most closely associated with the variability in creatinine clearance. In conclusion, renal transplant patients with lipid abnormalities display renoprotective activity of fluvastatin, possibly due to its lipid-lowering and antioxidant effects.


Assuntos
Anticolesterolemiantes/uso terapêutico , Ácidos Graxos Monoinsaturados/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Indóis/uso terapêutico , Transplante de Rim/fisiologia , Complicações Pós-Operatórias/tratamento farmacológico , Apolipoproteínas/sangue , Colesterol/sangue , LDL-Colesterol/sangue , Creatinina/sangue , Creatinina/urina , Fluvastatina , Humanos , Malondialdeído/sangue , Pessoa de Meia-Idade , Análise de Regressão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...